A bombshell undercover report has exposed a sprawling and audacious scheme within China’s healthcare sector, revealing how private psychiatric hospitals in Hubei province allegedly turned medical insurance fraud into a systematic business model. The investigation, published by Beijing News, details how hospitals recruited healthy individuals as “extras,” fabricated their medical records, and billed the state for fictitious treatments. This case of systemic insurance fraud not only highlights vulnerabilities in China’s critical public health fund but has also dragged one of the stock market’s healthcare giants, Aier Eye Hospital Group, into a fierce storm of public scrutiny and regulatory questioning.
Key Findings from the Investigation
The Beijing News report, based on undercover work in Xiangyang and Yichang cities, paints a picture of a well-organized operation targeting China’s basic medical insurance funds. The implications are severe for investor confidence in private healthcare operators and for the integrity of a system designed to protect public welfare.
- Hospitals are alleged to have used “free hospitalization” and “free transportation” as bait to recruit villagers with no mental illness, systematically fabricating their diagnoses and treatment records.
- Per-patient fraud is estimated at nearly 50,000 yuan (approx. $7,000) annually, with one hospital worker claiming 100 such “patients” could generate 5 million yuan in illicit revenue.
- The scandal has directly implicated Xiangyang Hengtaikang Hospital, which is ultimately controlled by Aier Eye Hospital’s billionaire founder and chairman, Bang Chen (陈邦).
- This incident follows a pattern of prior regulatory penalties against Aier Eye subsidiaries for insurance fund violations and questions about its charitable donations.
Unpacking the Mechanics of the Fraud
The scheme’s brazenness lies in its operational transparency within the involved hospitals. Staff members reportedly openly discussed the fabrication process, indicating a normalized culture of fraud rather than isolated malfeasance.
The Recruitment and Fabrication Pipeline
Hospitals employed dedicated “market personnel” who traveled to villages with lists to recruit “patients.” Once admitted, the fabrication began immediately. The investigation documented a case where a villager seeking help for alcohol dependence was diagnosed on paper with “alcohol-induced mental disorder.” Nurses and orderlies were reportedly complicit, with one orderly telling an undercover reporter they “invented about 130 yuan in treatment fees per day,” amounting to roughly 4,000 yuan monthly per patient. Cross-referencing medical insurance settlement statements confirmed this daily fictitious fee, solidifying the evidence of systemic insurance fraud.
Financial Scale and Coercive Practices
The financial motive is clear. With an estimated 50,000 yuan siphoned per person per year, the scheme treated public healthcare funds as a predictable revenue stream. Furthermore, patients were allegedly forced to stay for住院 periods nearly three times longer than national standards, maximizing fraudulent billings. The report also noted referral kickbacks, with staff receiving 400 yuan for each “patient” they brought in. In some extreme instances, even hospital security guards and orderlies were admitted as patients to further exploit the system.
Aier Eye Hospital’s Controversial Connection and Damage Control
The story escalated from a local healthcare scandal to a national corporate crisis when ownership links led to Aier Eye Hospital Group, a blue-chip stock with a market capitalization exceeding 100 billion yuan. This connection raises profound questions about corporate governance, oversight, and ultimate responsibility in complex corporate structures.
The Ownership Trail to Chairman Bang Chen
Corporate registry data reveals that Xiangyang Hengtaikang Hospital is fully owned by Hunan Hengtaikang Rehabilitation Medical Industry Development Co., Ltd. This company is nearly 80% owned by Aier Medical Investment Group, whose controlling shareholder is Aier Eye Hospital’s founder and chairman, Bang Chen (陈邦). This chain of ownership placed the chairman of a publicly listed medical giant at the apex of a company embroiled in a serious fraud investigation.
The “Independent Operation” Defense
After three days of mounting pressure, Aier Eye Hospital issued a public statement on February 6th. Its core argument was one of strict separation. The company asserted that Xiangyang Hengtaikang Hospital is a “fourth-level subsidiary” within the Aier Medical Investment Group structure, is not consolidated into Aier Eye Hospital’s financial statements, and operates completely independently in terms of equity, business, finance, and personnel.
The statement further clarified that Chairman Bang Chen is merely an investor in Aier Medical Investment Group and does not participate in the hospital’s daily operations, holding “no decision-making or management power” over its诊疗 practices or医保 fund usage. Aier expressed support for a thorough investigation and stated that Chen had urged the hospital to conduct its own internal review. However, the market and public remain skeptical. Can a controlling shareholder truly absolve himself of all responsibility for a company engaged in alleged systemic insurance fraud simply by claiming a lack of direct management? This incident tests the limits of the “corporate veil” in the court of public opinion and potentially with regulators.
A Pattern of Problematic Practices: Is This an Isolated Incident?
For seasoned market observers, this psychiatric hospital scandal is not Aier Eye Hospital’s first encounter with controversy surrounding ethics and compliance. A pattern of similar issues suggests deeper systemic or cultural challenges within parts of its extended network.
Prior Violations Across the Aier Network
Long before this scandal, various Aier Eye subsidiaries faced penalties for manipulating insurance funds. For example, the Xiangshan Aier Eye Hospital was fined 130,000 yuan for “substituting project charges.” Branches in Yangjiang, Benxi, and Foshan have been cited and had funds recovered for overcharging and fabricating services. Notably, just last month, Nanchang Aier Eye Hospital Co., Ltd. was slapped with a heavy fine of 770,000 yuan for医保 violations. These repeated infractions paint a picture of a company where aggressive billing practices, bordering on or crossing into fraud, have been a recurring problem.
Questions on Charity and Fund Flows
In October 2025, an investigation by NetEase’s Qingliu Studio raised separate red flags. Titled “The Mystery of Charity Fund Reflux in Eye Hospitals: How Donations from Aier Eye and Others Circle Back,” the report suggested that donations made by Aier Eye to various charitable foundations ultimately found their way back to the company through opaque channels. While not directly related to insurance fraud, this pattern of alleged “circular charity” further damages the group’s reputation for integrity and ethical operation, suggesting a corporate culture overly focused on financial engineering.
Broader Implications for China’s Healthcare Sector and Investors
This case of systemic insurance fraud transcends a single company or region. It serves as a critical stress test for China’s regulatory framework and exposes significant risks for investors in the private healthcare space.
Regulatory Crackdown and Market Fallout
The Chinese government has been in a multi-year campaign to safeguard its basic medical insurance funds, which are considered the public’s “life-saving money.” The National Healthcare Security Administration (国家医疗保障局) has consistently strengthened auditing and increased penalties for fraud. This high-profile case will undoubtedly trigger intensified scrutiny of all psychiatric and specialty hospitals, particularly private ones in lower-tier cities. Investors must price in higher regulatory risks and potential for severe financial penalties, license revocations, and reputational damage that can evaporate market value overnight. The immediate dip in Aier’s stock price following the news is a testament to this vulnerability.
Due Diligence and Governance as Investment Imperatives
For institutional investors and fund managers, this scandal is a stark reminder. Due diligence must extend beyond the financials of a listed parent company to probe the practices and compliance culture of its entire ecosystem, including subsidiaries, affiliated entities, and joint ventures. Governance structures that allow controlling shareholders to distance themselves from operational misconduct in affiliated companies are a major red flag. Investors should demand greater transparency, independent oversight on boards of subsidiaries, and clear accountability lines. The systemic insurance fraud in Hubei shows that what happens in an obscure fourth-level subsidiary can swiftly become a material crisis for a mainboard-listed leader.
Navigating the Aftermath: What Comes Next?
The exposure of this alleged fraud scheme opens a new chapter of accountability and reform. The response from regulators, the company, and the market will set important precedents.
First, regulatory authorities are expected to move swiftly. Investigations will likely expand from the named hospitals to their ownership networks and potentially to similar institutions in other regions. Penalties could be severe, including massive fines, reimbursement demands, and criminal prosecution of individuals involved. Second, Aier Eye Hospital Group faces a monumental task of reputation management. Its statement of separation may satisfy some legal definitions, but it must now demonstrate concrete action—such as commissioning a truly independent audit, overhauling governance of its investment portfolio, and taking visible steps to ensure such scandals cannot be linked to its name again. Finally, for the investment community, this is a case study in ESG (Environmental, Social, and Governance) risk materialization. The “S” and “G” factors—social responsibility through ethical treatment of patients and public funds, and governance of complex structures—have directly triggered financial and reputational damage.
The story of “extras” in psychiatric wards is more than a tale of local corruption; it is a warning siren for China’s capital markets. It highlights how vulnerabilities in a vital public system can be exploited for profit and how those profits can entangle even the most successful listed companies. As the investigation unfolds, market participants worldwide will be watching closely to see if this instance of systemic insurance fraud leads to systemic change in oversight, corporate accountability, and the protection of China’s healthcare ecosystem.